3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
78
Carcinoma, Non-Small-Cell Lung
43
Nasopharyngeal Carcinoma
24
Lung Neoplasms
23
Breast Neoplasms
14
Cholangiocarcinoma
13
Lymphoma, Large B-Cell, Diffuse
12
Neoplasm Metastasis
11
Ovarian Neoplasms
10
Lymphoma, Extranodal NK-T-Cell
10
Recurrence
9
Biliary Tract Neoplasms
9
Urinary Bladder Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasms
6
Nasopharyngeal Neoplasms
6
Lymphoma
6
Lymphoma, T-Cell, Peripheral
5
Uterine Cervical Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
4
Rectal Neoplasms
4
Hodgkin Disease
4
Head and Neck Neoplasms
4
Gallbladder Neoplasms
4
Colonic Neoplasms
4
Carcinoma, Transitional Cell
4
Adenocarcinoma of Lung
4
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, T-Cell
3
Interventions
camrelizumab
2
apatinib
2
sintilimab
1
Vinorelbine
1
Pemetrexed
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Respiratory Tract Diseases
×
Gemcitabine
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled